BR112022011426A2 - Uso de inibidores de atr em combinação com inibidores de parp - Google Patents

Uso de inibidores de atr em combinação com inibidores de parp

Info

Publication number
BR112022011426A2
BR112022011426A2 BR112022011426A BR112022011426A BR112022011426A2 BR 112022011426 A2 BR112022011426 A2 BR 112022011426A2 BR 112022011426 A BR112022011426 A BR 112022011426A BR 112022011426 A BR112022011426 A BR 112022011426A BR 112022011426 A2 BR112022011426 A2 BR 112022011426A2
Authority
BR
Brazil
Prior art keywords
inhibitors
combination
cancer
atr
rnase
Prior art date
Application number
BR112022011426A
Other languages
English (en)
Portuguese (pt)
Inventor
Koehler Maria
Zimmermann Michal
Roulston Anne
Original Assignee
Repare Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repare Therapeutics Inc filed Critical Repare Therapeutics Inc
Publication of BR112022011426A2 publication Critical patent/BR112022011426A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112022011426A 2019-12-11 2020-12-11 Uso de inibidores de atr em combinação com inibidores de parp BR112022011426A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962946876P 2019-12-11 2019-12-11
PCT/US2020/064662 WO2021119523A1 (en) 2019-12-11 2020-12-11 Use of atr inhibitors in combination with parp inhibitors

Publications (1)

Publication Number Publication Date
BR112022011426A2 true BR112022011426A2 (pt) 2022-08-30

Family

ID=76316464

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011426A BR112022011426A2 (pt) 2019-12-11 2020-12-11 Uso de inibidores de atr em combinação com inibidores de parp

Country Status (12)

Country Link
US (2) US20210177856A1 (cg-RX-API-DMAC7.html)
EP (1) EP4072551A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023506787A (cg-RX-API-DMAC7.html)
KR (1) KR20220128350A (cg-RX-API-DMAC7.html)
CN (1) CN115103677A (cg-RX-API-DMAC7.html)
AU (1) AU2020402108A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022011426A2 (cg-RX-API-DMAC7.html)
CA (1) CA3164203A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022001540A1 (cg-RX-API-DMAC7.html)
IL (1) IL293810A (cg-RX-API-DMAC7.html)
MX (1) MX2022007163A (cg-RX-API-DMAC7.html)
WO (1) WO2021119523A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210097124A (ko) 2018-10-30 2021-08-06 리페어 세라퓨틱스 인크. 화합물, 약제 조성물, 및 화합물 제조 방법 및 atr 키나제 억제제로서의 이것들의 사용 방법
KR20220035925A (ko) 2019-07-22 2022-03-22 리페어 세라퓨틱스 인크. Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체
JP2024522736A (ja) * 2021-06-16 2024-06-21 リペア セラピューティクス インコーポレイテッド がん治療のためのparp阻害剤と組み合わせたatr阻害剤の使用
EP4504208A1 (en) * 2022-04-07 2025-02-12 Repare Therapeutics Inc. Methods of using atr inhibitors
KR20250023494A (ko) * 2022-06-15 2025-02-18 아스트라제네카 아베 암 치료를 위한 병용 요법
WO2024164089A1 (en) * 2023-02-09 2024-08-15 Repare Therapeutics Inc. Use of atr inhibitors in the treatment of cancers with high tumor mutational burden
CN117159725B (zh) * 2023-04-06 2024-07-05 上海交通大学医学院附属仁济医院 通过dna水凝胶促进小分子药物结晶达到缓释效果的方法
WO2024243078A1 (en) * 2023-05-19 2024-11-28 Leapfrog Bio, Inc. Hsp90 inhibitors for the treatment of cancer
JP2026518747A (ja) * 2023-05-23 2026-06-09 ザ フランシス クリック インスティテュート リミテッド Alt陽性がんの治療のための標的

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG150548A1 (en) * 2003-12-01 2009-03-30 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
TWI656121B (zh) * 2014-08-04 2019-04-11 德商拜耳製藥公司 2-(嗎啉-4-基)-1,7-萘啶
EP3585365B1 (en) * 2017-02-24 2021-08-25 Bayer Pharma Aktiengesellschaft Combination of atr kinase inhibitors with parp inhibitors
KR20210097124A (ko) * 2018-10-30 2021-08-06 리페어 세라퓨틱스 인크. 화합물, 약제 조성물, 및 화합물 제조 방법 및 atr 키나제 억제제로서의 이것들의 사용 방법
KR20220035925A (ko) * 2019-07-22 2022-03-22 리페어 세라퓨틱스 인크. Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체

Also Published As

Publication number Publication date
JP2023506787A (ja) 2023-02-20
KR20220128350A (ko) 2022-09-20
MX2022007163A (es) 2022-08-25
EP4072551A1 (en) 2022-10-19
IL293810A (en) 2022-08-01
WO2021119523A8 (en) 2021-08-05
EP4072551A4 (en) 2023-11-15
CN115103677A (zh) 2022-09-23
AU2020402108A1 (en) 2022-07-14
US20240350505A1 (en) 2024-10-24
US20210177856A1 (en) 2021-06-17
WO2021119523A1 (en) 2021-06-17
CA3164203A1 (en) 2021-06-17
CL2022001540A1 (es) 2023-01-13

Similar Documents

Publication Publication Date Title
BR112023024942A2 (pt) Uso de inibidores de atr em combinação com inibidores de parp para tratamento de câncer
MX2022007163A (es) Uso de inhibidores de atr en combinacion con inhibidores de parp.
CR20230500A (es) Métodos para inhibir ras
BR112022007627A2 (pt) Compostos moduladores do glp-1r
MX2020010368A (es) Compuestos dirigidos a brm y métodos de uso asociados.
BR112016001457A2 (pt) Inibidores de fatores de transcrição e usos dos mesmos
BR112018071023A2 (pt) combinações para o tratamento de neoplasmas utilizando o direcionamento de células inativas e inibidores da mitose
BR112018008746A8 (pt) composições e métodos para a inibição de atividade de arginase
BR112022004699A2 (pt) Vs-6063 em combinação com ch5126766 para o tratamento de câncer
BR112019010265A2 (pt) anticorpos anti_cd137 inovadores e usos dos mesmos
UY37803A (es) Métodos y composiciones para tratar un evento de sangrado en un sujeto que padece hemofilia
MX2018013847A (es) Metodos para tratar cancer de piel administrando un inhibidor de pd-1.
BR112022009631A2 (pt) Combinações de inibidores de dgk e antagonistas do ponto de checagem
BR112015020290A2 (pt) métodos para tratar um câncer, para prevenir câncer, para inibir proliferação, para tratar terapeuticamente um mamífero, para tratar uma disfunção, para reduzir níveis de proteína spp1, para tratar terapeuticamente um câncer, para tratar um indivíduo e para inibir proliferação celular, artigo, anticorpos e usos
BR112022000713A2 (pt) Imidazopirimidinas como inibidores de eed e o uso das mesmas
BR112015025944A8 (pt) composição compreendendo inibidores do caminho do hedgehog e uso dos referidos inibidores
BR112015014090A2 (pt) intensificador de inibidores de zeste homólogo 2
MX385750B (es) Compuestos y métodos para la degradación mejorada de proteinas específicas.
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
BR112022021910A2 (pt) Inibidores da proteína bcl-2
BR112017009440A2 (pt) uso de composições que modulam a estrutura de cromatina quanto à doença do enxerto versus hospedeiro (gvhd)
BR112014028991A2 (pt) triazóis como inibidores de kv3
CL2022001368A1 (es) Uso de inhibidores de sglt-2 en el secado de mamíferos no humanos
BR112018070547A2 (pt) agonistas de rara para o tratamento de aml e mds
BR112021016783A2 (pt) Composições e métodos para tratar laminopatias

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2858 DE 14-10-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.